Aiforia expands clinical product portfolio with new AI model in Europe
Summary
- Aiforia launched a new CE-IVD-marked AI model for detecting lymph node metastases, enhancing its clinical product portfolio in Europe.
- The company collaborated with the University of Bern to develop this model, which can save pathologists up to 40% of their time in lymph node screening.
- We expect Aiforia's expanding product portfolio to support new sales and provide opportunities for additional sales to existing customers, but it does not alter our current forecasts.
- Aiforia now has 15 CE-IVD approved models, covering approximately 60% of histopathology sample volumes, strengthening its competitive position in the EU market.
This content is generated by AI. You can give feedback on it in the Inderes forum.
Translation: Original published in Finnish on 9/5/2025 at 6:07 pm EEST.
Aiforia announced in a press release on Friday that it is launching a new CE-IVD-marked clinical AI solution for detecting lymph node metastases. The new Aiforia® Lymph Node Metastasis AI model is intended for the detection and quantification of breast cancer, melanoma, and colorectal cancer metastases in lymph nodes. The product expansion further supports the company's growth prospects but does not change our forecasts.
The product launch further expands the already extensive product family within the clinical segment
We have been expecting Aiforia to continue expanding its clinical product portfolio and the company has received several CE-IVD approvals in 2025, following the easing of a regulatory bottleneck that lasted a few years, so the news was not a surprise. According to the press release, the latest solution can save pathologists up to 40% of their time in the laborious and time-consuming lymph node screening process. The AI model was developed in collaboration with the University of Bern.
One of Aiforia's competitive advantages and strategic goals is to build a comprehensive suite of AI tools for various cancer diagnostics for pathology laboratories, all based on a single platform. Each new CE-IVD-approved product strengthens the company's offering and competitive position, while increasing the value of Aiforia's platform for both existing and new customers. Aiforia now has 15 CE-IVD approved models, and the company estimates that its models will cover approximately 60% of histopathology sample volumes in 2025 (figure below). In our view, the company's product offering is already quite extensive in the EU market, and we do not believe its breadth will often be an obstacle for local pathology laboratories to acquire the software.
Source: Aiforia H1/2025 earnings release briefing
We believe the expanding product portfolio supports Aiforia's new sales and provides opportunities for additional sales to existing customers. However, a single product launch does not cause pressure to change our estimates, as we expect the company to continue gaining market share through continuous new customer acquisitions and successful expansions of existing customer accounts.
Aiforia Technologies equips pathologists and researchers in preclinical and clinical laboratories with software to translate images into discoveries, decisions and diagnoses. The company's products and services are used for medical image analysis, across a variety of fields such as oncology and neuroscience. Aiforia Technologies is headquartered in Finland.
Read more on company pageKey Estimate Figures29.08.2025
| 2024 | 25e | 26e | |
|---|---|---|---|
| Revenue | 2.9 | 3.7 | 5.3 |
| growth-% | 18.9 % | 29.3 % | 45.0 % |
| EBIT (adj.) | -12.2 | -10.7 | -12.6 |
| EBIT-% (adj.) | -427.8 % | -289.8 % | -236.3 % |
| EPS (adj.) | -0.41 | -0.38 | -0.40 |
| Dividend | 0.00 | 0.00 | 0.00 |
| Dividend % | |||
| P/E (adj.) | neg. | neg. | neg. |
| EV/EBITDA | neg. | neg. | neg. |
Forum discussions
